Insight Molecular Diagnostics Debt-to-Assets Ratio Growth & History (IMDX)

Insight Molecular Diagnostics's debt-to-assets ratio was 0.13 for fiscal 2025.

View full Insight Molecular Diagnostics company overview

Insight Molecular Diagnostics annual debt-to-assets ratio history

Insight Molecular Diagnostics annual debt-to-assets ratio

Fiscal yearPeriod endedDebt-to-assets ratioChangeGrowth
20252025-12-310.130.03+26.91%
20242024-12-310.100.06+165.05%
20232023-12-310.040.04+3177.21%
20222022-12-310.00
20202020-12-310.010.00+107.41%
20192019-12-310.00−0.06−94.61%
20182018-12-310.06−0.16−72.73%
20172017-12-310.220.18+408.51%
20162016-12-310.040.04
20152015-12-310.00

Insight Molecular Diagnostics debt-to-assets ratio trends

Over the last five fiscal years, Insight Molecular Diagnostics's debt-to-assets ratio increased from 0.01 to 0.13, a change of 0.12. The latest reported quarter, Q2 2026, shows 0.08.

About the metric

What the debt-to-assets ratio means

The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.

Calculation and source

How debt-to-assets is calculated

TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Insight Molecular Diagnostics source filings ↗

Community posts

It’s quiet here.

No posts about IMDX yet. Start the conversation.

Write the first post